913297-16-2

Basic information

• Product Name: methyl 3-amino-2-(methylamino)benzoate
• Synonyms: methyl 3-amino-2-(methylamino)benzoate
• CAS NO: 913297-16-2
• Molecular Weight: 180.206
• Mol File: 913297-16-2.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: methyl 3-amino-2-(methylamino)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 3-amino-2-(methylamino)benzoate(913297-16-2)
• EPA Substance Registry System: methyl 3-amino-2-(methylamino)benzoate(913297-16-2)

Safety Data

• Hazardous Substances Data: 913297-16-2(Hazardous Substances Data)

Upstream product

• 913297-15-1 methyl 2-(methylamino)-3-nitrobenzoate 
• 53553-14-3 2-chloro-3-nitrobenzoic acid methyl ester 
• 3970-35-2 2-chloro-3-nitrobezoic acid 
• 34128-16-0 2-chloro-3-nitro-benzoyl chloride 

Downstream Products

• 1022249-27-9 3-chloro-4-((4-chloro-7-(1-ethylpropyl)-1-methyl-1Hbenzimidazol-2-yl)oxy)-5-methylbenzamide 
• 1022251-49-5 3-chloro-4-{[4-chloro-7-(1-ethylpropyl)-1-methyl-1H-benzimidazol-2-yl]oxy}-5-methylbenzoic acid 
• 913299-18-0 methyl 4-chloro-2-[(4-chloro-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazole-7-carboxylate 

Relevant articles and documents

Discovery of a Potent FLT3 Inhibitor (LT-850-166) with the Capacity of Overcoming a Variety of FLT3 Mutations

Secondary mutations of FLT3 have become the main mechanism of FLT3 inhibitor resistance that presents a significant clinical challenge. Herein, a series of pyrazole-3-amine derivatives were synthesized and optimized to overcome the common secondary resistance mutations of FLT3. The structure-activity relationship and molecular dynamics simulation studies illustrated that the ribose region of FLT3 could be occupied to help address the obstacle of secondary mutations. Among those derivatives, compound 67 exhibited potent and selective inhibitory activities against FLT3-ITD-positive acute myeloid leukemia (AML) cells and possessed equivalent potency against transformed BaF3 cells with a variety of secondary mutations. Besides, cellular mechanism assays demonstrated that 67 strongly inhibited phosphorylation of FLT3 and its downstream signaling factors, as well as induced cell cycle arrest and apoptosis in MV4-11 cells. In the MV4-11 xenograft models, 67 exhibited potent antitumor potency without obvious toxicity. Taken together, these results demonstrated that 67 might be a drug candidate for the treatment of FLT3-ITD-positive AML.

THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS

The present invention relates to novel Thiazole Derivatives, compositions comprising the Thiazole Derivatives, and methods for using the Thiazole Derivatives for treating or preventing a proliferative disorder, an anti-proliferative disorder, inflammation, arthritis, a central nervous system disorder, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral infection, a fungal infection, or a disorder related to the activity of a protein kinase.

BENZIMIDAZOLE COMPOUNDS

There is provided a compound of the formula (1) wherein R1 is an optionally substituted C1-10 alkyl; R2 is H, or a C1-6 alkyl which may be substituted with 1 to 3 substituents; R3 is a 5- or 6-membered aromatic group which may be substituted with 1 to 5 substituents, wherein the 5- or 6-membered aromatic group may be fused with a 5- or 6- membered ring which may be substituted with 1 to 3 C1-6 alkyls; R4 is a hydrogen, a halogen, a hydroxy, a cyano, a C1-6 alkyl or a C1-6 alkoxy; Z is -O-, -S-, -SO-, -SO2-, or - NR5- wherein R5 is a hydrogen or a C1-6 alkyl; or a salt thereof or a prodrug thereof, which have CRF receptor antagonist activity and use thereof.